Buerger's disease primary prevention: Difference between revisions

Jump to navigation Jump to search
 
Line 4: Line 4:


==Overview==
==Overview==
An effective measure for the primary prevention of Buerger's disease includes [[smoking cessation]]. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] as a means of preventing cravings is permissible.  
An effective measure for the primary prevention of Buerger's disease is [[smoking cessation]]. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] for preventing cravings is permissible.  


==Primary Prevention==
==Primary Prevention==
*An effective measure for the primary prevention of Buerger's disease includes [[smoking cessation]].<ref name="pmid10995867">{{cite journal |vauthors=Olin JW |title=Thromboangiitis obliterans (Buerger's disease) |journal=N. Engl. J. Med. |volume=343 |issue=12 |pages=864–9 |date=September 2000 |pmid=10995867 |doi=10.1056/NEJM200009213431207 |url=}}</ref><ref name="pmid2225420">{{cite journal |vauthors=Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR |title=The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease) |journal=Circulation |volume=82 |issue=5 Suppl |pages=IV3–8 |date=November 1990 |pmid=2225420 |doi= |url=}}</ref><ref name="pmid14718836">{{cite journal |vauthors=Ohta T, Ishioashi H, Hosaka M, Sugimoto I |title=Clinical and social consequences of Buerger disease |journal=J. Vasc. Surg. |volume=39 |issue=1 |pages=176–80 |date=January 2004 |pmid=14718836 |doi=10.1016/j.jvs.2003.08.006 |url=}}</ref>
*An effective measure for the primary prevention of Buerger's disease is [[smoking cessation]].<ref name="pmid10995867">{{cite journal |vauthors=Olin JW |title=Thromboangiitis obliterans (Buerger's disease) |journal=N. Engl. J. Med. |volume=343 |issue=12 |pages=864–9 |date=September 2000 |pmid=10995867 |doi=10.1056/NEJM200009213431207 |url=}}</ref><ref name="pmid2225420">{{cite journal |vauthors=Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR |title=The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease) |journal=Circulation |volume=82 |issue=5 Suppl |pages=IV3–8 |date=November 1990 |pmid=2225420 |doi= |url=}}</ref><ref name="pmid14718836">{{cite journal |vauthors=Ohta T, Ishioashi H, Hosaka M, Sugimoto I |title=Clinical and social consequences of Buerger disease |journal=J. Vasc. Surg. |volume=39 |issue=1 |pages=176–80 |date=January 2004 |pmid=14718836 |doi=10.1016/j.jvs.2003.08.006 |url=}}</ref>
*This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] as a means of preventing cravings is permissible.
*This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of [[bupropion]] and [[varenicline]] for preventing cravings is permissible.


==References==
==References==

Latest revision as of 19:42, 1 May 2018

Buerger's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Buerger's Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Buerger's disease primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Buerger's disease primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Buerger's disease primary prevention

CDC on Buerger's disease primary prevention

Buerger's disease primary prevention in the news

Blogs on Buerger's disease primary prevention

Directions to Hospitals Treating Buerger's disease

Risk calculators and risk factors for Buerger's disease primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

An effective measure for the primary prevention of Buerger's disease is smoking cessation. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.

Primary Prevention

  • An effective measure for the primary prevention of Buerger's disease is smoking cessation.[1][2][3]
  • This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.

References

  1. Olin JW (September 2000). "Thromboangiitis obliterans (Buerger's disease)". N. Engl. J. Med. 343 (12): 864–9. doi:10.1056/NEJM200009213431207. PMID 10995867.
  2. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR (November 1990). "The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease)". Circulation. 82 (5 Suppl): IV3–8. PMID 2225420.
  3. Ohta T, Ishioashi H, Hosaka M, Sugimoto I (January 2004). "Clinical and social consequences of Buerger disease". J. Vasc. Surg. 39 (1): 176–80. doi:10.1016/j.jvs.2003.08.006. PMID 14718836.

Template:WH Template:WS